The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).
 
Matthew E. Burge
Stock and Other Ownership Interests - Atcor Medical (I); Cochlear; CSL Limited; Gilead Sciences; Pfizer (I); Ramsay Health; Sirtex Medical (I)
Honoraria - Merck Serono; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Roche/Genentech
Travel, Accommodations, Expenses - Ipsen; Merck Serono; Roche/Genentech
 
Hui-Li Wong
Research Funding - Roche (Inst)
 
Belinda Lee
No Relationships to Disclose
 
Jeanne Tie
Honoraria - Sirtex Medical
Consulting or Advisory Role - Bayer; Eisai
Research Funding - Sysmex (Inst)
Travel, Accommodations, Expenses - Amgen; Roche; Sirtex Medical
 
Suzanne Kosminder
No Relationships to Disclose
 
Kathryn Maree Field
No Relationships to Disclose
 
Ben Tran
No Relationships to Disclose
 
Jayesh Desai
No Relationships to Disclose
 
Sumitra Ananda
No Relationships to Disclose
 
Peter Gibbs
Honoraria - Alchemia; Amgen; Bayer; Merck; Roche; Sirtex Medical
Research Funding - Pfizer (Inst); Roche (Inst)